TearLab Corp fka TEAR

[ash111]

TEAR july 2016, C.T order filed, 3 months later co.entered into Material
Definitive Agreement ( PRN). Mar 27, 2017 another C.T order... more on the works beside several Catalysts ahead.

Interesting coverage forecast sales of $145m on only a modest market penetration. Edison 14 May 2015 : "If it can achieve even modest market penetration it may reach potential yearly card sales of $145m. This assumes 10% provider penetration, 25 patients per day, 25% of patients tested and 175 clinic days per year".

Edison also said that "The current EV of $73.4m", "May not reflect market potential". current cap is only $13m (about 5m O/S) a/o May 15, 2017, extremely undervalued relating EV mentioned.

This coverage was written exactly 2 years ago before TEAR Achieved those Milestones (Achieved more than a modest market penetration as Edison forecasted):


1. Approval in the Republic of Korea by the Ministry of Health and Welfare

2. Commercial launch in the Republic of India

3. A/o May 12, 2017- approval in the Federative Republic of Brazil (the largest market in Latin America with a population of over 200 million).
CEO of TearLab Corporation said, "We are pleased to complete these major milestones for TearLab’s international business as we continue to increase our global footprint in key strategic markets. Due to their size and growing dry eye populations, these three markets represent significant opportunity for us to expand our business and continue toward our goal of making osmolarity testing a global standard of care in diagnosing dry eye disease.”

Although company still facing net loss investors always looking forward. company has an impressive grow rate:

Revenues $:
2012 3,960 first commercial launch of the TearLab Osmolarity System
2013 14,645
2014 19,718
2015 25,156
2016 28,014 expenses cut by 30% too.

More estimations made by Tearlab in 2016 confirmed Edison Valuation. June 2016 Presentation:

1. Current Run Rate - $27 million
2. Potential current customer footprint - $98 million
3. Market opportunity with current U.S. infrastructure $194 million

Strong IP Portfolio:

U.S. 11 Issued Patents
ROW 25 Issued Patents
Pending 18 Patents
https://www.tearlab.com/investors/TEAR_Investor_Presentation_LD_Micro_Final_20160609_Rev.pdf

I do expect revenues boost due solid approvals, cash/share $2.6 a/o today.
"We anticipate that our cash and cash equivalents...will be sufficient to sustain our operations into the first quarter of 2018"

Reduced both operating expenses & loss by 60% & 75% past 2 earnings.
beats on Revenues.

Updates May 15,2017 CC: https://seekingalpha.com/article/4073481-tearlabs-tear-ceo-seph-jensen-q1-2017-results-earnings-call-transcript